XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Instruments
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments
7.Derivative Instruments
The Company is exposed to certain market risks relating to its ongoing business operations. From time to time, the Company enters into derivative instrument arrangements to manage various risks including interest rate risk.
Interest rate swap contracts
The Company has entered into interest rate swap contracts to manage its exposure to changes in interest rates. Such contracts are intended to economically hedge the LIBOR component of future interest payments associated with outstanding borrowings under the Company’s Amended and Restated Credit Agreement.
A summary of the Company’s interest rate swap contracts with a collective notional amount of $2.3 billion outstanding as of September 30, 2021 is as follows:
Contract End Date
Fixed Interest Rates1
Notional Amount at inception
(in thousands)
December 20210.743%$485,000 
December 20222.204%$300,000 
March 2023
1.954% - 2.413%
$450,000 
December 20231.862%$200,000 
May 2024
0.435% - 0.440%
$300,000 
May 20250.678%$300,000 
May 2026
0.909% - 0.910%
$300,000 
1 Fixed interest rates payable by WEX. Counterparties pay floating rate equal to the one-month USD LIBOR.
The following table presents information on the location and amounts of gains and losses from interest rate swap contract derivatives:
(In thousands)Three Months Ended September 30,Nine Months Ended September 30,
Derivatives Not Designated as Hedging InstrumentsLocation of Gain (Loss) Recognized in the Statement of Operations2021202020212020
Interest rate swap contracts – unrealized portionNet unrealized gain (loss) on financial instruments$6,527 $3,774 $20,008 $(32,722)
Interest rate swap contracts – realized portionFinancing interest expense$(7,037)$(5,438)$(18,575)$(10,336)
Derivative instruments and their related gains and losses are reported within cash flows from operating activities within the condensed consolidated statements of cash flows. See Note 12, Fair Value, for more information regarding the valuation of the Company’s derivatives.